MultiCell announces new cancer therapeutics preclinical results PBR Staff WriterPublished 13 August 2012 MultiCell Technologies has revealed updated preclinical research results for MCT-465 and MCT-485.
MCT-465 and MCT-485 are cancer therapeutics, which use TLR3 signaling technology.
During the trials, MCT-485 showed in vitro dose-effect cytotoxicity on several human hepatocellular carcinoma cell lines while MCT-465 showed no cytotoxicity or anti-proliferative effect.
The results will further aid mechanistic and in vivo studies exploring the safety, effectiveness and utility of MCT-465 and MCT-485 as therapeutic agents to treat hepatocellular carcinoma and other cancers.
Primary liver cancer results from Hepatitis B and Hepatitis C infection and is the most common cancer in some parts of the world with more than 1 million new cases diagnosed each year.